Maat Pharma Phase III microbiome trial hits endpoints as stock soar
The French company has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.
09 January 2025
09 January 2025
The French company has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.